SURPASS-2: The Only Head-to-Head Trial The SURPASS-2 trial (NEJM, 2021) is the most important study in this comparison because it directly tested tirzepatide against semaglutide in 1,879 patients with type 2 diabetes over 40 weeks
Common side effects may include: Addressing these risks with professional guidance helps ensure a safer experience when using peptides for bodybuilding
Results are based on self-reported data from Josie members on personalized treatment plans, including compounded GLP-1 medications and provider consultations
In clinical trials, people who stopped semaglutide often regained much of the weight they had lost
No membership fees, no insurance hoops, and HSA/FSA eligibility make treatment accessible to working men nationwide
Some providers prefer to start patients on oral semaglutide to establish tolerability before escalating to injectable tirzepatide